ArticleJournal of molecular modeling2025
Investigate the potential inhibitors of sphingosine kinase 1 (SphK1) with molecular dynamics and artificial intelligence drug design methods.
Article in Journal of molecular modeling, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
contextSphingosine kinase 1 (SphK1) is a sphingosine kinase that can catalyze the phosphorylation of sphingosine to generate sphingosine-1-phosphate. The J-type channel of SPHK1 plays an important role in processes such as cell signaling. Therefore, this study aims to investigate the interaction mechanism between Epidanshenspiroketallactone, PF-543, and SPHK1 in the J-type channel, and to design new small molecules using AI Drug Design (AIDD). Molecular dynamics (MD) simulations reveal that hydrophobic interactions and π-π stacking are of critical significance in stabilizing the J-channel conformation of Sphk1. With MD and AIDD methods, our research provides a novel potential approach for the exploration and design of SphK1 inhibitors.
methodsThe binding mechanism of Epidanshenspiroketallactone and PF-543 with SphK1 was predicted by the molecular dynamics (MD) method using Gromacs-2022-2. Molecular docking was carried out with MolAICal, and the structures were visualized with the Pymol software. The MD simulation force field was selected as the AMBER99SB force field, the temperature was set at 310 K, and the total MD simulation time was 7.2 μs. A recurrent neural network-long short-term memory (RNN-LSTM) machine model was employed for the design of novel inhibitors.
Indexed as
Identifiers
40996560What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.